Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 468-473
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.06.008
Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience
Daniele Vallisa,
Patrizia Bernuzzi,
Luca Arcaini,
Stefano Sacchi,
Vittorio Callea,
Roberto Marasca,
Antonio Lazzaro,
Elena Trabacchi,
Elisa Anselmi,
Anna Lisa Arcari,
Carlo Moroni,
Raffaella Bertè,
Mario Lazzarino,
Luigi Cavanna
From the Department of Oncology and Hematology, G. da Saliceto Hospital, Piacenza; Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Paiva; Department of Oncology and Hematology, University of Modena, Modena; Haematology Division, Azienda Ospedaliera of Reggio Calabria, Reggio Calabria, Italy
Address reprint requests to Daniele Vallisa, MD, Department of Oncology and Hematology, G. da Saliceto Hospital, Piacenza, Via Taverna 49, 29100 Piacenza, Italy; e-mail: d.vallisa{at}ausl.pc.it
PURPOSE: Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role in the development of both hepatocellular carcinoma and B-cell non-Hodgkin's lymphoma (B-NHL). The biologic mechanisms underlying the lymphomagenic activity of the virus so far are under investigation. In this study, the role of antiviral (anti-HCV) treatment in B-NHL associated with HCV infection is evaluated.
PATIENTS AND METHODS: Thirteen patients with histologically proven low-grade B-NHL characterized by an indolent course (ie, doubling time no less than 1 year, no bulky disease) and carrying HCV infection were enrolled on the study. All patients underwent antiviral treatment alone with pegilated interferon and ribavirin. Response assessment took place at 6 and 12 months.
RESULTS: Of the twelve assessable patients, seven (58%) achieved complete response and two (16%) partial hematologic response at 14.1 ± 9.7 months (range, 2 to 24 months, median follow-up, 14 months), while two had stable disease with only one patient experiencing progression of disease. Hematologic responses (complete and partial, 75%) were highly significantly associated to clearance or decrease in serum HCV viral load following treatment (P = .005). Virologic response was more likely to be seen in HCV genotype 2 (P = .035), while hematologic response did not correlate with the viral genotype. Treatment-related toxicity did not cause discontinuation of therapy in all but two patients, one of whom, however, achieved complete response.
CONCLUSION: This experience strongly provides a role for antiviral treatment in patients affected by HCV-related, low-grade, B-cell NHL.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc.,
May 1, 2008;
19(5):
835 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Portlock, P. Hamlin, A. Noy, W. Chey, C. A. Gaydos, L. Palomba, I. Schwartz, S. Corcoran, L. Rosenzweig, D. Walker, et al.
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy
Ann. Onc.,
February 1, 2008;
19(2):
254 - 258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub
Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation
Rheumatology,
August 1, 2007;
46(8):
1234 - 1242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al.
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
Ann. Onc.,
February 1, 2007;
18(2):
346 - 350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni
Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369)
Ann. Onc.,
February 1, 2007;
18(2):
401 - 403.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.-C. Piette, and P. Cacoub
Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.
Arch Intern Med,
October 23, 2006;
166(19):
2101 - 2108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Visco, L Arcaini, E Brusamolino, S Burcheri, A Ambrosetti, M Merli, E Bonoldi, M Chilosi, A Viglio, M Lazzarino, et al.
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy
Ann. Onc.,
September 1, 2006;
17(9):
1434 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al.
Splenic marginal zone lymphoma: a prognostic model for clinical use
Blood,
June 15, 2006;
107(12):
4643 - 4649.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yanagi, T. Shimizu, H. Ujiie, M. Ito, R. Abe, Y. Tsuji-Abe, S. Hige, and H. Shimizu
Peginterferon alfa-2b for mycosis fungoides.
Arch Dermatol,
May 1, 2006;
142(5):
649 - 651.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. M. Ferreri, E. Viale, M. Guidoboni, A. G. Resti, C. De Conciliis, L. Politi, A. A. Lettini, F. Sacchetti, R. Dolcetti, C. Doglioni, et al.
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa
Ann. Onc.,
May 1, 2006;
17(5):
769 - 772.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Suarez, O. Lortholary, O. Hermine, and M. Lecuit
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Blood,
April 15, 2006;
107(8):
3034 - 3044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. de Jonge and J. Verweij
The Epothilone Dilemma
J. Clin. Oncol.,
December 20, 2005;
23(36):
9048 - 9050.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Bertoni and E. Zucca
State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6415 - 6420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mazzaro, M. Spina, and U. Tirelli
Regression of Low-Grade Non-Hodgkin's Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection
J. Clin. Oncol.,
July 1, 2005;
23(19):
4470 - 4471.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Vallisa, P. Bernuzzi, A. Lazzaro, E. Trabacchi, E. Anselmi, A. L. Arcari, C. Moroni, R. Berte, and L. Cavanna
In Reply:
J. Clin. Oncol.,
July 1, 2005;
23(19):
4471 - 4471.
[Full Text]
[PDF]
|
 |
|
|